News
We send the latest information from SMC Laboratories.
Phenex Pharmaceuticals AG’s presentation at EASL the International Liver CongressTM 2019 in Vienna, Austria.
SMC announced that Phenex Pharmaceuticals AG presented results of a study using STAM™ model at oral presentation at EASL the International Liver CongressTM 2019 in Vienna, Austria, April 10-19, 2019. Title: LXR inverse agonists reduce steatosis and fibrosis in the STAM™ mouse model but also improve insulin sensitivity in a high fat diet mouse clamp…
Pharmaxis Ltd’s publication on Journal of Cellular and Molecular Medicine.
SMC announced that Pharmaxis Ltd has published the results of a study using STAM™ model on Journal of Cellular and Molecular Medicine. Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis” Read more….https://www.ncbi.nlm.nih.gov/pubmed/30536539
Publication on Scientific Reports.
SMC announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Scientific Reports: Title: “Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/30850637
New services using acute liver failure a rodent model
We are pleased to announce today the launch of new services using a mouse model for acute liver failure (ALF), TAA-induced ALF model. LEARN MORE…
Genentech, Inc’s publication on NPJ Precision Oncology.
SMC announced that Genentech, Inc. has published the results of a study using STAM™ model on NPJ Precision Oncology. Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” Read more….https://www.ncbi.nlm.nih.gov/pubmed/30456308